2012 “Fierce 15” — The Best and Brightest in Biotech — Announced Today at BioPharm America™ in Boston

MassBioSarah MacDonald, +1-617-674-5115orEBD GroupErin Righetti, +1-760-930-0500

This year’s announcement of the best and brightest emerging biotech companies took place at BioPharm America™ in Boston today. The Fierce 15 is a much anticipated who’s who list of annual awardees created by recognizing the 15 most promising private biotech companies in the world.

The 2012 winners are AC Immune SA, Alkeus Pharmaceuticals, Angiochem, Aragon Pharmaceuticals, bluebird bio, Celladon Corporation, Ember Therapeutics, Enanta Pharmaceuticals, EnVivo Pharmaceuticals, Foundation Medicine, Mersana Therapeutics, miRagen, Okairos, PROSENSA, and Seaside Therapeutics.

“Fierce 15 companies represent some of the most exciting ‘partnerable’ companies in the industry. We are really pleased to be working with — and to help them celebrate the tenth anniversary of this award,” said , President of EBD Group.

“We like to recognize biotechs who boldly set out to blaze new paths. And we recognize that in an industry like drug development, not everyone makes it to the finish line. But there’s more here than a willingness to accept risk,” said Editor-in-Chief . “If anything, the growing appetite for risk reflected in this year’s Fierce 15 raises the odds against successful drug development, but improves the odds of a genuine breakthrough.”

The thrilled award winners commented on their election:

The event, organized by EBD Group, the leading partnering firm for the life science industry, is being held September 19–21, 2012, at the Westin Boston Waterfront in Boston, MA, in collaboration with the Massachusetts Biotechnology Council (MassBio).

For more coverage on this year’s Fierce 15, go to

Video coverage of the Fierce 15 awards and other highlights from BioPharm America 2012 will be posted online at

BioPharm America is where biotech industry partnerships get started. Meet face-to-face with biotech and pharma executives from around the world to identify and enter strategic relationships. Equipped with partneringONE®, BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®.

Additional links and information:

Follow BioPharm America 2012 on Twitter: (hashtag: #BPA12)

MassBio, a not-for-profit organization that represents and provides services and support for the Massachusetts biotechnology industry, is the nation’s oldest biotechnology trade association. Founded in 1985, MassBio is committed to advancing the development of critical new science, technology and medicines that benefit people worldwide. Representing over 600 biotechnology companies, academic institutions, research hospitals, and service organizations involved in life sciences and healthcare, MassBio works to advance policy and promote education, while providing member programs and events, industry information, and services.

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations and include:

EBD Group’s sophisticated web-based partnering service, , is also used as the partnering engine at numerous third-party events around the world, and is the open online community of life science dealmakers that enhances partnering experiences all year long.

Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.

EBD Group has offices in the USA and Europe.

For more information please visit .

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.